Drug intelligence / Profile preview

pSD11-Livin1

Development stage
Preclinical
Lead developer
Zhengzhou University
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

pSD11-Livin1 is an experimental gene therapy construct designed to silence the expression of the Livin gene (also known as BIRC7 or ML-IAP) through RNA interference. It consists of a pSD11 plasmid vector that expresses a specific short hairpin RNA (shRNA) sequence targeting the mRNA of Livin, a member of the Inhibitor of Apoptosis Protein (IAP) family. Livin is frequently overexpressed in various malignancies, such as bladder cancer, lung cancer, and melanoma, where it functions to inhibit programmed cell death by neutralizing caspases. By delivering shRNA to tumor cells, pSD11-Livin1 aims to downregulate Livin protein levels, thereby restoring apoptotic signaling, inhibiting tumor cell proliferation, and potentially increasing the efficacy of concurrent chemotherapeutic agents. Research on this construct has been primarily conducted in preclinical models by academic institutions.

Other names
Livin-shRNA plasmidpSD11-Livin shRNA expression vectorpSD-11-Livin shRNA expression vectorpSD 11-Livin shRNA expression vector
02

Targets

BIRC7

Beyond the preview

Go deeper on pSD11-Livin1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on pSD11-Livin1.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call